LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    NewsRx Health. September 29, 2024, p255.